Literature DB >> 17032095

Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy.

Patrick Gosselin1, Robert Ladouceur, Charles M Morin, Michel J Dugas, Lucie Baillargeon.   

Abstract

This study evaluated the specific effectiveness of cognitive-behavior therapy (CBT) combined with medication tapering for benzodiazepine discontinuation among generalized anxiety disorder (GAD) patients by using a nonspecific therapy control group. Sixty-one patients who had used benzodiazepines for more than 12 months were randomly assigned to the experimental conditions. Nearly 75% of patients in the CBT condition completely ceased benzodiazepine intake, as compared with 37% in the control condition. Results of the 3-, 6-, and 12-month follow-ups confirmed the maintenance of complete cessation. Discontinuation rates remained twice as high in the CBT condition. The number of patients who no longer met GAD criteria was also greater in the CBT condition. The addition of specific CBT components thus seemed to facilitate benzodiazepine tapering among patients with GAD. Copyright 2006 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17032095     DOI: 10.1037/0022-006X.74.5.908

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  23 in total

Review 1.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2011-10-27

Review 2.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2007-11-20

Review 3.  Approaches to Deprescribing Psychotropic Medications for Changed Behaviours in Long-Term Care Residents Living with Dementia.

Authors:  Stephanie L Harrison; Monica Cations; Tiffany Jessop; Sarah N Hilmer; Mouna Sawan; Henry Brodaty
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

4.  Can psychotherapists function as their own controls? Meta-analysis of the crossed therapist design in comparative psychotherapy trials.

Authors:  Fredrik Falkenström; John C Markowitz; Hanske Jonker; Björn Philips; Rolf Holmqvist
Journal:  J Clin Psychiatry       Date:  2012-10-30       Impact factor: 4.384

5.  Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation.

Authors:  Michael W Otto; R Kathryn McHugh; Naomi M Simon; Frank J Farach; John J Worthington; Mark H Pollack
Journal:  Behav Res Ther       Date:  2010-04-28

6.  A randomized clinical trial of cognitive-behavioral therapy and applied relaxation for adults with generalized anxiety disorder.

Authors:  Michel J Dugas; Pascale Brillon; Pierre Savard; Julie Turcotte; Adrienne Gaudet; Robert Ladouceur; Renée Leblanc; Nicole J Gervais
Journal:  Behav Ther       Date:  2009-06-06

7.  Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population.

Authors:  Meldon Kahan; Angela Mailis-Gagnon; Lynn Wilson; Anita Srivastava
Journal:  Can Fam Physician       Date:  2011-11       Impact factor: 3.275

8.  Cognitive behavioural therapy and applied relaxation for generalized anxiety disorder: a time series analysis of change in worry and somatic anxiety.

Authors:  Michel J Dugas; Kylie Francis; Stéphane Bouchard
Journal:  Cogn Behav Ther       Date:  2009

Review 9.  Withdrawing Benzodiazepines in Patients With Anxiety Disorders.

Authors:  Malcolm Lader; Andri Kyriacou
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

Review 10.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.